Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus
Deepak L. Bhatt,Tilo Grosser,Jing-fei Dong,Douglas Logan,Walter Jeske,Dominick J. Angiolillo,Andrew L. Frelinger,Lanyu Lei,Juan Liang,Jason E. Moore,Byron Cryer,Upendra Marathi
DOI: https://doi.org/10.1016/j.jacc.2016.11.050
IF: 24
2017-02-01
Journal of the American College of Cardiology
Abstract:BACKGROUND: A limitation of aspirin is that some patients, particularly those with diabetes, may not have an optimal antiplatelet effect.OBJECTIVES: The goal of this study was to determine if oral bioavailability mediates nonresponsiveness.METHODS: The rate and extent of serum thromboxane generation and aspirin pharmacokinetics were measured in 40 patients with diabetes in a randomized, single-blind, triple-crossover study. Patients were exposed to three 325-mg aspirin formulations: plain aspirin, PL2200 (a modified-release lipid-based aspirin), and a delayed-release enteric-coated (EC) aspirin. Onset of antiplatelet activity was determined by the rate and extent of inhibition of serum thromboxane B<sub>2</sub> (TXB<sub>2</sub>) generation. Aspirin nonresponsiveness was defined as a level of residual serum TXB<sub>2</sub> associated with elevated thrombotic risk (<99.0% inhibition or TXB<sub>2</sub> >3.1 ng/ml) within 72 h after 3 daily aspirin doses.RESULTS: The rate of aspirin nonresponsiveness was 15.8%, 8.1%, and 52.8% for plain aspirin, PL2200, and EC aspirin, respectively (p < 0.001 for both comparisons vs. EC aspirin; p = 0.30 for comparison between plain aspirin and PL2200). Similarly, 56% of EC aspirin-treated subjects had serum TXB<sub>2</sub> levels >3.1 ng/ml, compared with 18% and 11% of subjects after administration of plain aspirin and PL2200 (p < 0.0001). Compared with findings for plain aspirin and PL2200, this high rate of nonresponsiveness with EC aspirin was associated with lower exposure to acetylsalicylic acid (63% and 70% lower geometric mean maximum plasma concentration [C<sub>max</sub>] and 77% and 82% lower AUC<sub>0-t</sub> [area under the curve from time 0 to the last time measured]) and 66% and 72% lower maximum decrease of TXB<sub>2</sub>, with marked interindividual variability.CONCLUSIONS: A high proportion of patients treated with EC aspirin failed to achieve complete inhibition of TXB<sub>2</sub> generation due to incomplete absorption. Reduced bioavailability may contribute to "aspirin resistance" in patients with diabetes. (Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients; NCT01515657).
cardiac & cardiovascular systems